PRESS RELEASE

from PharmaSGP Holding SE (isin : DE000A2P4LJ5)

EQS-Adhoc: PharmaSGP Holding SE releases forecast for full year 2023

EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Forecast
PharmaSGP Holding SE releases forecast for full year 2023

14-March-2023 / 18:17 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

 

PharmaSGP Holding SE releases forecast for full year 2023

 

Gräfelfing, March 14, 2023 The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has agreed on the forecast for consolidated revenue and adjusted consolidated earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) of the PharmaSGP Group for the financial year 2023 based on an evaluation that was completed today of current data on the previous and expected business development in the current financial year. In view of the continued positive business development as well as the positive outlook, the Management Board expects consolidated revenues in the range of € 91 million to € 96 million for the financial year 2023 (previous year, based on preliminary figures: € 85.8 million). In addition, the Management Board forecasts adjusted EBITDA of between € 30 million and € 34 million (previous year, based on preliminary figures: € 28.2 million), corresponding to an adjusted EBITDA margin of 33.0% to 35.4% (previous year, based on preliminary figures: 32.9%).

The preliminary figures for the full financial year 2022 will be published as planned on March 15, 2023.

Note: The key figure "adjusted EBITDA" is not a key figure according to IFRS. Information on the adjustments used to derive adjusted EBITDA is available in the PharmaSGP Holding SE Annual Report 2021 on p. 40 (available at https://ir.pharmasgp.com).

 

##### End of the ad hoc announcement ####

 

Contact:
cometis AG
Claudius Krause
Phone: +49 (0)611-20585528
Mail: ir@pharmasgp.com

 


14-March-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language:English
Company:PharmaSGP Holding SE
Lochhamer Schlag 1
82166 Gräfelfing
Germany
E-mail:ir@pharmasgp.com
Internet:https://pharmasgp.com
ISIN:DE000A2P4LJ5
WKN:A2P4LJ
Listed:Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich
EQS News ID:1582443

 
End of AnnouncementEQS News Service

1582443  14-March-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1582443&application_name=news&site_id=symex
See all PharmaSGP Holding SE news